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Objective: This study aims to assess the efficacy and safety of Gelesis100, a novel, nonsystemic, 
superabsorbent hydrogel to treat overweight or obesity.
Methods: The Gelesis Loss Of Weight (GLOW) study was a 24-week, multicenter, randomized, double-
blind, placebo-controlled study in patients with BMI  ≥  27 and  ≤  40 kg/m2 and fasting plasma glucose ≥ 90 
and ≤ 145 mg/dL. The co-primary end points were placebo-adjusted weight loss (superiority and 3% margin 
super-superiority) and at least 35% of patients in the Gelesis100 group achieving ≥ 5% weight loss.
Results: Gelesis100 treatment caused greater weight loss over placebo (6.4% vs. 4.4%, P = 0.0007), 
achieving 2.1% superiority but not 3% super-superiority. Importantly, 59% of Gelesis100-treated patients 
achieved weight loss of ≥ 5%, and 27% achieved ≥ 10% versus 42% and 15% in the placebo group, 
respectively. Gelesis100-treated patients had twice the odds of achieving ≥ 5% and ≥ 10% weight loss 
versus placebo (adjusted OR: 2.0, P = 0.0008; OR: 2.1, P = 0.0107, respectively), with 5% responders having 
a mean weight loss of 10.2%. Patients with prediabetes or drug-naive type 2 diabetes had six times the 
odds of achieving ≥ 10% weight loss. Gelesis100 treatment had no apparent increased safety risks.
Conclusions: Gelesis100 is a promising new nonsystemic therapy for overweight and obesity with a highly 
desirable safety and tolerability profile.
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Introduction
Obesity increases the risk for several life-threatening diseases (1-5). 
Importantly, the increased risk of death is not limited to severe or Class 
II (BMI 35 to 40 kg/m2) and Class III (BMI > 40 kg/m2) obesity but 
begins in patients who have a BMI of 25 kg/m2 (6,7) and continues in 
Class I obesity (BMI 30 to 35 kg/m2) (8). In fact, 40% of BMI-related 
deaths and 37% of disability-adjusted life years in 2015 occurred in 
patients with overweight (4), and Class I obesity was associated with 
reduced life expectancy by 2 to 4 years (8).
Only 2% of patients with overweight or obesity receive antiobesity drug 
therapy despite the overwhelming evidence of the growing burden of 
excess weight (7,9). In contrast, more than 80% of patients with type 
2 diabetes (T2D) are prescribed antidiabetes pharmacotherapy (10). 
Considering that obesity is a major cause of T2D, these realities are par-
adoxical. Multiple studies documented that therapeutic inertia is high in 
the management of weight, particularly in patients with lower BMI (11). 
The highest rates of weight management interventions by primary care 
physicians occur for patients in the Class III obesity category and the 
lowest for patients in the overweight category; rates also correlated with 
the presence of comorbidities (12,13). A 2016 obesity survey among 
health care professionals reported that 60% of antiobesity pharmaco-
therapy is disproportionally prescribed for patients in Class II or Class 
III obesity (11). Health care providers addressing weight  management 
issues are challenged by numerous barriers, but the concerns about tol-
erability and safety of currently available interventions likely contribute 
to this resistance to treat obesity (14).
There is thus an urgent need for therapies that increase patients’ odds 
for achieving clinically meaningful weight loss with little or no addi-
tional safety risk compared with lifestyle interventions. Such therapies 
could allow clinicians to intervene earlier in the overweight and obesity 
continuum and prevent progression or delay associated comorbidities 
while helping to overcoming the current therapeutic inertia.
Gelesis100 is a nonsystemic, superabsorbent hydrogel developed for 
the treatment of overweight or obesity. It is made from two naturally 
derived building blocks, modified cellulose cross-linked with citric 
acid, that create a three-dimensional matrix. Orally administered in 
capsules with water before a meal, Gelesis100 particles rapidly absorb 
water in the stomach and homogeneously mix with ingested foods. 
When hydrated, the recommended dose of Gelesis100 occupies about 
one-fourth of the average stomach volume. Rather than forming one 
large mass, it creates thousands of small individual gel pieces with the 
elasticity (firmness) of solid ingested foods (e.g., vegetables) without 
caloric value (15). Gelesis100 maintains its three-dimensional structure 
and mechanical properties during transit through the small intestine. 
Once it arrives in the large intestine, the hydrogel is partially broken 
down by enzymes and loses its three-dimensional structure along with 
most of its absorption capacity. The released water is reabsorbed, and 
the remaining cellulosic material is expelled in the feces. Gelesis100 is 
considered a medical device because it achieves its primary intended 
purpose through mechanical modes of action (16) consistent with 
mechanobiology constructs (17). Gelesis100 received a Nonsignificant 
Risk designation by the Food and Drug Administration.
Herein, we report results from the Gelesis Loss Of Weight (GLOW) 
pivotal study that assessed the safety and efficacy of Gelesis100 in 
patients with overweight or obesity, with and without T2D. Results of 
GLOW’s 24-week extension (GLOW-EX) study are also presented.
Methods
Study design and treatment
GLOW was a multicenter, randomized, double-blind, placebo- 
controlled, pivotal study assessing the safety and efficacy of Gelesis100 
administered for 24 weeks on body weight in adults with overweight or 
obesity, with or without T2D. The 24-week open-label extension study 
(GLOW-EX) was offered to the last 52 patients who completed treat-
ment (placebo or Gelesis100) and lost ≥ 3% of their body weight from 
baseline. GLOW and GLOW-EX were conducted in accordance with 
the Good Clinical Practice guidelines as defined by the International 
Conference on Harmonisation, the Declaration of Helsinki, the 
International Organization for Standardization 14155:2011 (Clinical 
Investigation of Medical Devices for Human Subjects), and all 
applicable federal and local medical device guidelines and regula-
tions. Institutional review boards, independent ethics committees, 
and European Competent Authorities approved the study protocol and 
informed consent documents. A study design schematic of GLOW and 
GLOW-EX can be found in Supporting Information Figure S1.
For 168 days, patients self-administered three capsules containing 
either 2.25 g of Gelesis100 or placebo with 500 mL of water 20 to 
30 minutes before lunch and dinner. Patients were prescribed a hypoca-
loric diet of 300 kcal/d below their calculated energy requirement (with 
45% to 50% of daily calorie intake from carbohydrates, ≤ 30% from 
fat, and 20% to 25% from protein). Patients were instructed to perform 
daily moderate-intensity exercise (e.g., 30 minutes of walking/day) and 
maintain their smoking habits during the study.
Patients
Eligible patients were men and nonpregnant, nonlactating women aged 
22 to 65 years with BMI  ≥  27 and  ≤ 40 and fasting plasma  glucose 
(FPG)  ≥  90 and  ≤ 145 mg/dL at screening (visit 1). Patients with 
BMI < 30 were required to have at least one of the following comor-
bidities: dyslipidemia (defined as serum low-density lipoprotein choles-
terol [LDL-C]  ≥  130 and  <  190 mg/dL and/or triglycerides [TG]  ≥  150 
and  < 500 mg/dL), hypertension (supine systolic blood pressure 
[SBP]  ≥  140 and  < 160 mmHg and/or supine diastolic blood pressure 
[DBP]  ≥  90 and  < 95 mmHg), or drug-naive or metformin-treated T2D.
Patients were excluded from the study if they were of childbearing 
potential and not using contraception; had type 1 diabetes; or had a 
history of eating disorders (except for mild binge eating disorder), sig-
nificant gastrointestinal disorders, and gastric bypass or other gastro-
intestinal surgery. Patients with hemoglobin A1c > 8.5% (> 69 mmol/
mol), who had a weight change > 3 kg within 3 months of screening, or 
who required medications administered with meals were also excluded. 
Depression was not an exclusion criterion unless it required a drug 
causing weight change.
Efficacy assessments
GLOW study. The co-primary efficacy end points were the percent 
change in body weight from baseline (visit 2) to day 171 (visit 13) and 
the percent of patients who lost ≥ 5% body weight from baseline to 
day 171. Secondary efficacy end points included percent change in 
body weight in patients with impaired FPG (IFG) at baseline, change 
in plasma glucose status in IFG, percent change in plasma glucose in 
IFG and T2D, change in BMI, and change in hemoglobin A1c in T2D 
from baseline to day 171. Selected tertiary efficacy end points included 
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the percent of patients who lost ≥  10% body weight and percent 
change from baseline to day 171 in estimated excess body weight, 
serum insulin, homeostasis model assessment-insulin resistance 
(HOMA-IR), LDL-C, HDL-C, TG, waist circumference, and supine 
and standing SBP and DBP. Baseline measurements were assessed on 
day 0. Treatment began on day 1 and ended on day 169. There were 
approximately 2 days between the end of treatment and study end 
point assessments (day 171) to allow the remaining Gelesis100 to be 
eliminated from the gastrointestinal tract.
GLOW-EX study. The GLOW-EX study evaluated the durability of 
the efficacy of Gelesis100 over a 48-week exposure and assessed the 
incremental weight loss benefit by adding Gelesis100 after patients’ 
successful weight loss with lifestyle modification (placebo) over the 
initial 24 weeks. The co-primary efficacy end points included the 
percent change in body weight from GLOW baseline (day 0) to day 
339 and from GLOW-EX baseline (day 171) to day 339 as well as the 
percent of patients who lost ≥ 5% body weight from GLOW baseline to 
day 339 and from GLOW-EX baseline to day 339.
Figure 1 Patient disposition. GLOW, Gelesis Loss Of Weight; EX, extension; ITT, intention-to-treat; PP, per-protocol.
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TABLE 1 Baseline demographics and disease characteristics (ITT population)
Parametera Gelesis100 (n = 223) Placebo (n = 213) P value
Age (y) 48.2 (9.9) 47.8 (10.9) 0.734
Sex, n (%) 1.0000
Female 125 (56.1) 120 (56.3)
Male 98 (43.9) 93 (43.7)
Race, n (%) 0.7345
White 189 (84.8) 180 (84.5)
Black/African American 26 (11.7) 24 (11.3)
Other 8 (3.5) 9 (4.2)
Ethnicity, n (%) 0.3217
Hispanic or Latino 11 (4.9) 16 (7.5)
Weight, kgb 97.6 (14.4) 100.6 (15.3) 0.0348
BMI, kg/m2 33.5 (3.2) 34.1 (3.2) 0.0784
Waist circumference, cmb 108.3 (10.7) 110.7 (11.0) 0.0249
Weight categories, n (%) 0.1457
Overweight 26 (11.7) 21 (9.9)
Obesity Class I 129 (57.8) 108 (50.7)
Obesity Class II 68 (30.5) 84 (39.4)
Comorbidities, n (%) 0.7557
Dyslipidemiac 154 (69.1) 154 (72.3) 0.4406
Hypertensiond 67 (30.0) 60 (28.2) 0.4638
Prediabetese 66 (29.6) 66 (31.0) 0.6748
T2D 21 (9.4) 25 (11.7) 0.3405
FPG, mg/dL
Normoglycemia 91.7 (5.7) 91.8 (5.6) 0.8986
Prediabetes 107.7 (5.7) 108.4 (6.5) 0.5414
Drug-naive T2D 133.7 (42.2) 138.2 (8.8) 0.4800
Treated T2D (metformin) 116.2 (19.9) 117.4 (20.3) 0.8690
Insulin, mU/L
Normoglycemia 9.4 (4.9) 10.1 (5.4) 0.2904
Prediabetes 13.7 (7.3) 12.6 (7.9) 0.4110
Drug-naive T2D 42.2 (58.0) 26.2 (15.7) 0.5047
Treated T2D (metformin) 17.2 (21.7) 13.3 (9.1) 0.5408
HOMA-IR
Normoglycemia 2.1 (1.1) 2.3 (1.2) 0.3493
Prediabetes 3.7 (2.0) 3.4 (2.1) 0.3999
Drug-naive T2D 15.5 (23.8) 8.8 (5.0) 0.4891
Treated T2D (metformin) 5.6 (8.6) 4.1 (3.4) 0.5426
Current smokers, n (%) 23 (10.3) 24 (11.3) 0.7599
Postmenopausal, n (%) 57/125 (45.6) 51/120 (42.5) 0.6996
Untreated 55 (96.5) 50 (98.0) 1.0000
Treated (estrogen) 2 (3.5) 1 (2.0)
aData presented as mean (SD) unless otherwise specified.
bWeight and waist circumference parameters significantly different between groups at baseline (P = 0.0348 and 0.0249, respectively).
cDyslipidemia defined as serum low-density lipoprotein cholesterol ≥ 130 and <190 mg/dL and/or triglycerides ≥ 150 and <500 mg/dL.
dHypertension defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg.
ePrediabetes was defined based on 1 FPG measurement at visit 2.
FPG, fasting plasma glucose; HOMA-IR, homeostasis model assessment-insulin resistance; T2D, type 2 diabetes; ITT, intention-to-treat.
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Safety assessments
The safety and tolerability of Gelesis100 were assessed by recording all 
adverse events (AEs) and serious AEs (SAEs) and monitoring results from 
physical examinations, vital sign measurements, and fasting clinical lab-
oratory tests, which included hematology, blood chemistry, and vitamin 
levels. For the GLOW study, all AEs and SAEs reported after random-
ization and up to 28 days after the last treatment administration (day 197) 
were recorded. For the GLOW-EX study, all AEs and SAEs reported up 
to 28 days after the last treatment administration (day 365) were recorded.
Statistical analysis
Sample size was calculated using PASS power analysis soft-
ware (NCSS, LLC, Kaysville, Utah). A total of 430 patients were 
randomized 1:1 to have 172 completers per treatment group based 
on 20% dropout rate. This sample size was expected to provide 
85% statistical power to detect a difference of ≥ 3% weight loss and 
90% statistical power to establish that the difference between the 
two treatment groups was greater than 0 (superiority with a standard 
deviation [SD] of 5.0% and a type I error of 0.05 in a two-sided test). 
The co-primary end points were placebo-adjusted percent weight 
loss super-superiority with a margin of 3% and at least 35% of 
patients on Gelesis100 achieving at least 5% weight loss. A prespeci-
fied analysis of simple superiority was also performed. Stratification 
factors using characteristics obtained at the screening visit were used 
to balance treatment group assignments. The stratification was based 
on groups of countries, sex, BMI, and screening FPG at the time of 
randomization.
Figure 2 Weight loss with Gelesis100 versus placebo treatment during the GLOW study among patients in the ITT population. (A) Percent change in body weight from 
baseline (day 0) to day 171 (after 2 days of washout) by treatment group. Error bars represent standard error of the mean (SEM). (B) Percent responders with ≥ 5% 
(P = 0.0008), ≥ 7.5% (P = 0.0017), or ≥ 10% (P = 0.0107) weight loss in all patients. (C) Percent change in excess body weight from baseline (day 0) to day 171 (after 2 
days of washout) by treatment group. Error bars represent SEM. (D) Adjusted odds ratio (95% confidence interval) for achieving ≥ 5% (2.0 [1.3-3.0]), ≥ 7.5% (2.1 [1.3-3.3]), 
and ≥ 10% (2.1 [1.2-3.8]) weight loss. *P < 0.05; **P < 0.001. All P values are from logistic regression models adjusted for baseline weight and stratification factors. GLOW, 
Gelesis Loss Of Weight; ITT, intention-to-treat.
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In the pilot clinical study First Loss Of Weight (FLOW), elevated FPG 
and particularly prediabetes status at baseline were associated with 
greater weight loss in patients treated with Gelesis100 (18). To evaluate 
this hypothesis further, GLOW included screening FPG as a stratifica-
tion factor.
Continuous variables are presented as mean (SD) unless otherwise 
specified. Statistical software SAS version 9.3 or later (SAS Institute, 
Inc., Cary, North Carolina) was used for statistical analysis. The pri-
mary efficacy analysis was performed using the intention-to-treat (ITT) 
population consisting of all randomized patients, with missing data 
imputed using a robust multiple imputation analysis (SAS PROC MI, 
SAS Institute). For the two treatment groups, analysis of covariance 
(ANCOVA) was performed to compare the percent change in body 
weight from baseline to day 171 (two-sided α = 0.05). The logit model 
was used to determine the percent body weight responders. Secondary 
and tertiary end points were analyzed using a closed test procedure with 
ANCOVA. All P values are from logistic regression models adjusted 
for baseline weight and stratification factors. HOMA-IR was calcu-
lated by multiplying fasting serum insulin (mU/L) by FPG (mmol/L) 
and dividing by 22.5.
Additional analyses included weight loss-related end points among FPG 
subgroups (based on two consecutive FPG measurements per American 
Diabetes Association guidelines) (19) who had no missing data (com-
pleters). An area under the curve (AUC) of the receiver operating char-
acteristic (ROC) was completed as a post hoc analysis to model the 
predictive power of early weight loss for responder status with the optimal 
point determined by the Youden index. The AUC ROC analysis optimized 
the balance between positive predictive value or percent of patients with 
early weight loss response who had ≥ 5% weight loss after 24 weeks and 
negative predictive value or the percent of patients with early weight loss 
response who had < 5% weight loss after 24 weeks. The cutoff for posi-
tive predictive value and negative predictive value was set at 80%.
The safety population was defined as any patient receiving at least 
one dose of investigational product after randomization. Safety data 
are reported as number of patients experiencing an event, using a 95% 
confidence interval (CI) for AE comparison across treatment groups. 
The 95% CI was calculated using the Clopper-Pearson method.
GLOW-EX effectiveness end points were assessed by comparing the 
95% CI from baseline of GLOW to day 171, and from baseline of 
TABLE 2 Change from baseline for weight-related and comorbidity parameters. 
Parameterb
Mean change (SD)a
LS mean difference 
(SD) 95% CI P valueGelesis100 (n = 223) Placebo (n = 213)
Weight-related
Weight, % –6.4 (5.8) –4.4 (5.5) –2.1 (0.6) (–3.2, –0.9) 0.0007
Body mass index, kg/m2 –2.1 (1.9) –1.5 (1.9) –0.6 (0.2) (–1.0, –0.2) 0.0039
Excess body weight, % –29.0 (30.1) –21.0 (25.7) –6.4 (2.9) (–12.2, –0.6) 0.0295
Waist circumference, cm –6.7 (5.6) –5.0 (5.9) –1.9 (0.6) (–3.1, –0.6) 0.0038
Parameterb
Mean change (95% CI)e
Difference (SD) 95% CI P valueGelesis100 (n = 223) Placebo (n = 213)
Comorbidity
Dyslipidemiac
LDL-C, % n = 83 n = 84
–4.7 (2.2) (–9.0, –0.3) 0.0347 –11.2 (–14.5, –7.8) –5.9 (–8.8, –3.0)
TG, % n = 58 n = 53
–11.0 (9.9) (–30.7, 8.7) 0.2694–18.0 (–30.0, –5.9) –8.0 (–23.3, 7.4)
Hypertensiond
SBP, mmHg
n = 38 n = 34
–1.0 (2.3) (–5.7, 3.6) 0.6528–9.3 (–12.4, –6.2) –9.2 (–12.8, –5.6)
DBP, mmHg –7.5 (–9.6, –5.4) –4.7 (–7.2, –2.2) –1.3 (1.4) (–4.1, 1.4) 0.3452
Conversion to  
normotensive, %f 68.4 44.1
OR
(1.0, 7.9) 0.04342.9
aData presented as mean change (SD) unless otherwise specified.
bParameters are percent change unless otherwise specified.
cDyslipidemia defined as LDL-C >130 mg/dL or TG >150 mg/dL at baseline (LDL-C/TG baseline values = 161/227 mg/dL for Gelesis100 and 159/222 mg/dL for placebo).
dHypertension is defined as SBP >140 mmHg or DBP >90 mmHg at baseline (SBP/DBP baseline values = 143.5/88.5 mmHg and 145.0/85.9 mmHg for Gelesis100 and 
placebo, respectively).
eCompleter data presented as mean (95% CI).
fOR and 95% CI from logistic regression model adjusted for stratification factors and baseline SBP and DBP.
LS, least squares; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; SBP, systolic blood pressure; DBP, diastolic blood pressure; OR, odds ratio.
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GLOW to day 339, with the overlapping 95% CI representing main-
tenance of the effect. Percent change in body weight from baseline 
of GLOW or GLOW-EX to day 339 and P values were determined 
using paired t tests (two-sided α = 0.05) for both treatment groups.
Results
Patient disposition and baseline demographics
Of the 904 patients screened for eligibility, 436 were randomized 
(223 patients allocated to the Gelesis100 group and 213 patients 
allocated to the placebo group), and 324 completed the treatment 
phase of the GLOW study (172 in the Gelesis100 group and 152 
in the placebo group) (Figure 1). A total of 112 patients were 
withdrawn from the study (51 [23%] in the Gelesis100 group 
and 61 [29%] in the placebo group). The most common 
reason for withdrawal by patient was for lifestyle or personal choice 
(Figure 1).
Demographics and baseline characteristics were overall similar 
between groups (Table 1). Patients were mostly middle-aged, white, 
and equally distributed across the treatment groups by sex. A total 
of 284 patients (70% of the Gelesis100 group and 61% of the pla-
cebo group) had either overweight or Class I obesity. Baseline weight 
Figure 3 Weight loss with Gelesis100 versus placebo treatment during the GLOW study among completers. (A) Percent responders with ≥ 5% 
(Gelesis100, n = 74; placebo, n = 42; P = 0.0079), ≥ 7.5% (Gelesis100, n = 49; placebo, n = 49; P = 0.0726), and ≥ 10% (Gelesis100, n = 29; 
placebo, n = 20; P = 0.4541) weight loss in normoglycemic completers (n = 226). (B) Adjusted odds ratio (95% confidence interval) of ≥ 5% 
(2.1 [1.2-3.7]), ≥ 7.5% (1.7 [1.0-3.0]), and ≥ 10% (1.3 [0.7-2.5]) weight loss achieved by normoglycemic completers between treatment groups. 
(C) Percent responders with ≥ 5% (Gelesis100, n = 23; placebo, n = 20; P = 0.1509), ≥ 7.5% (Gelesis100, n = 17; placebo, n = 9; P = 0.0272), and 
≥ 10% (Gelesis100, n = 14; placebo, n = 5; P = 0.0071) weight loss in completers with prediabetes or drug-naive T2D (n = 68). (D) Adjusted odds 
ratio (95% confidence interval) of ≥ 5% (2.2 [0.8-6.4]), ≥ 7.5% (3.4 [1.2-10.0]), and ≥ 10% (6.1 [1.6-22.8]) weight loss achieved by completers with 
prediabetes or drug-naive T2D between treatment groups. T2D, type 2 diabetes. *P < 0.05; **P < 0.01. All P values are from logistic regression 
models adjusted for baseline weight and stratification factors. GLOW, Gelesis Loss Of Weight.
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and waist circumference were significantly lower in the Gelesis100 
group versus placebo (P = 0.0348 and P = 0.0249, respectively). 
The primary end point analyses account for this difference, as base-
line BMI and weight were covariates in the ANCOVA models. At 
baseline, most patients had high normal FPG ≥ 90 mg/dL (136/223 
patients [61%] in the Gelesis100 group and 122/213 patients [57%] 
in the placebo group).
GLOW results
Efficacy. In the ITT population, there was a greater percent change 
in body weight from baseline to day 171 in the Gelesis100 group (mean 
−6.4% [SD 5.8%]) versus placebo (mean −4.4% [SD 5.5%]) (Figure 
2A), with a placebo-adjusted least squares mean difference of −2.1% 
(P = 0.0007) (Table 2). The study demonstrated superiority over 
placebo but not super-superiority with 3% margin.
Notably, significantly more patients treated with Gelesis100 achieved 
≥ 5% weight loss (co-primary end point) versus placebo (59% vs. 
42%) (Figure 2B), and 27% of patients treated with Gelesis100 
achieved ≥ 10% weight loss versus 15% of patients treated with pla-
cebo. Patients treated with Gelesis100 had twice the odds of achiev-
ing ≥ 5% weight loss versus placebo (adjusted odds ratio [OR]: 
2.0; P = 0.0008). For these responders, the mean weight loss was 
10.2% ± 4.1%. Similarly, Gelesis100-treated patients had twice the 
odds of achieving ≥ 7.5% (OR: 2.1; P = 0.0017) and ≥ 10% (OR: 2.1; 
P = 0.0107) weight loss (Figure 2D). Patients treated with Gelesis100 
sustained markedly greater weight loss over time without plateauing 
(Figure 2A).
Of the secondary end points, only reduction in BMI reached statis-
tical significance versus placebo (P = 0.0039). In addition to the 
percent of patients achieving ≥ 10% weight loss, the other tertiary 
end points that were statistically different were excess body weight 
(Figure 2C; P = 0.0295) and waist circumference (P = 0.0038) 
(Table 2).
Predictors of response. In a previous clinical study (FLOW), an 
association was observed between elevated FPG and greater treatment 
effect, particularly among patients with FPG ≥ 100 mg/dL at baseline 
(18). In the GLOW study, there were 32 patients in the Gelesis100 
TABLE 3 AUC ROC analysis for 5% responders in Gelesis100 and placebo groups. 
Percent change in 
weight from baseline Optimal threshold Sensitivity Specificity AUC SEa Lower 95% CIb Upper 95% CIb
Gelesis100
Visit 3, week 1 −0.9106 0.5657 0.7324 0.6795 0.0423 0.5966 0.7625
Visit 4, week 2 −1.3793 0.6000 0.7917 0.7727 0.0352 0.7037 0.8417
Visit 5, week 4 −2.2876 0.7400 0.8310 0.8515 0.0285 0.7956 0.9075
Visit 6, week 6 −2.8678 0.7600 0.8310 0.8811 0.0247 0.8326 0.9296
Visit 7, week 8 −3.0272 0.8485 0.8732 0.9105 0.0216 0.8683 0.9528
Visit 8, week 10 −3.1504 0.8485 0.8592 0.9175 0.0206 0.8772 0.9578
Visit 9, week 12 −3.4913 0.9000 0.8333 0.9242 0.0195 0.8859 0.9624
Visit 10, week 16 −4.2219 0.9100 0.8889 0.9590 0.0128 0.9339 0.9840
Visit 11, week 20 −4.1945 0.9600 0.8889 0.9818 0.0070 0.9681 0.9955
Visit 12, week 24 −5.1163 0.9500 1.0000 0.9965 0.0021 0.9924 1.0000
Placebo
Visit 3, week 1 −1.4541 0.4531 0.8636 0.6779 0.0443 0.5911 0.7647
Visit 4, week 2 −2.1179 0.5238 0.8636 0.7335 0.0416 0.6519 0.8151
Visit 5, week 4 −1.7578 0.7813 0.7614 0.8215 0.0348 0.7534 0.8897
Visit 6, week 6 −3.2967 0.6563 0.8864 0.8267 0.0348 0.7586 0.8948
Visit 7, week 8 −2.1951 0.8438 0.7614 0.8823 0.0269 0.8295 0.9350
Visit 8, week 10 −4.0948 0.6825 0.9318 0.8864 0.0257 0.8359 0.9368
Visit 9, week 12 −4.0000 0.7813 0.8864 0.9119 0.0219 0.8690 0.9549
Visit 10, week 16 −4.8048 0.8438 0.9342 0.9414 0.0185 0.9051 0.9777
Visit 11, week 20 −4.8908 0.9063 0.9342 0.9729 0.0113 0.9508 0.9951
Visit 12, week 24 −4.7668 0.9688 0.9773 0.9952 0.0030 0.9893 1.0011
The first time point in which sensitivity and specificity were both above 80% occurred at week 8 for Gelesis100 and week 16 for placebo (represented in bold).
Optimal threshold to predict 5% or greater weight loss at 24 weeks in Gelesis100 group is at least 3% weight loss at 8 weeks. Early responders achieved mean weight loss of 
9.9% at week 24 versus 2.1% for non-early responders.
When applying the threshold of 3% weight loss at 8 weeks to placebo group, mean weight loss of 8.9% at week 24 for early responders versus 1.5% for non-early responders 
was observed. However, the analysis for placebo group demonstrated predictive values >0.8 only at 16 weeks with weight loss threshold of 4.8%.
AUC, area under the curve; ROC, receiver operating characteristic.
aSE of AUC.
b95% CI for AUC.
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group and 36 patients in the placebo group with prediabetes (FPG ≥  
100 mg/dL and < 126 mg/dL) or drug-naive T2D (FPG ≥ 126 mg/dL), 
based on two consecutive FPG measurements at visit 1 and visit 2. 
The mean (SD) percent change in body weight from baseline to day 
171 was −8.1% (6.5%) and −5.6% (4.9%) for the Gelesis100 and placebo 
treatment groups, respectively (adjusted mean standard error [SE] 
difference of −2.5% [1.4]; P = 0.0820).
More patients with prediabetes or drug-naive T2D (53%) achieved 
≥ 7.5%, and almost half (44%) achieved ≥ 10% weight loss versus 25% 
and 14% of patients in the placebo group, respectively (Figure 3C). The 
odds of achieving ≥ 7.5% or ≥ 10% weight loss were 3.4 and 6.1 times 
higher in the Gelesis100 group versus the placebo group (P = 0.0272 
and 0.0071, respectively) (Figure 3D).
AUC ROC analysis showed that early response to Gelesis100 
treatment (≥ 3% weight loss from baseline at week 8) successfully 
predicted clinically meaningful weight loss (≥ 5%) at 24 weeks. 
More than 85% of patients who went on to achieve ≥ 5% weight loss 
at 6 months had lost ≥ 3% of body weight at 8 weeks. Notably, early 
responders achieved mean weight loss of 9.9% versus 2.1% in non-early 
responders at week 24 (Table 3). The placebo group did not reach the 
required threshold for sensitivity and specificity until near the end of 
treatment (Table 3).
Effect on cardiovascular risk factors. Overall, there were 
no significant differences between groups in the well-known 
cardiovascular risk factors such as LDL-C, HDL-C, TG, SBP, DBP, 
or insulin resistance estimated by HOMA-IR. However, in patients 
who started with elevated levels, those treated with Gelesis100 had a 
greater reduction in LDL-C levels (P = 0.0347) and greater conversion 
rate to normal blood pressure (P = 0.0434) (Table 2). Patients 
with elevated HOMA-IR at baseline treated with Gelesis100 had a 
reduction compared with the placebo group (P = 0.0080) (Figure 4). 
This improvement in HOMA-IR was mainly driven by a reduction in 
fasting serum insulin in the Gelesis100 group (P = 0.0102).
Safety. All 436 patients in the GLOW study are included in 
the safety analysis except for 2 patients in the placebo group who 
did not receive the investigational product. The most common 
AEs in both groups were gastrointestinal related, infections and 
infestations, and musculoskeletal and connective tissue disorders. 
The most common (>  5%) gastrointestinal AEs in the Gelesis100 
group were diarrhea, abdominal distension, infrequent bowel 
movements, flatulence, constipation, nausea, and abdominal pain. 
In the Gelesis100 group, 158 (85%) gastrointestinal AEs reported by 
84 (38%) patients were deemed possibly or probably related to the 
study treatment versus 105 (78%) AEs reported by 58 (28%) patients 
in the placebo group (P = 0.0248). Fifteen patients withdrew from 
the study because of an AE (eight in the Gelesis100 group and 
seven in the placebo group) before completing the treatment phase; 
five in the Gelesis100 group and four in the placebo group were 
considered probably or possibly related to the study treatment 
(Table 4).
Overall, gastrointestinal-related AEs were significantly different 
between groups (P = 0.0248). However, none of the individual gastro-
intestinal AEs, regardless of their level of severity, reached statistical 
significance. Most of these events were assessed as mild. The incidence 
of gastrointestinal events considered to be either moderate or severe 
was 39 events in 21 patients in the Gelesis100 group and 22 events in 
15 patients in the placebo group.
In the Gelesis100 group, eight patients reported a severe AE versus 
ten patients in the placebo group. The majority of severe AEs occurred 
within 3 months of randomization and were resolved within 2 weeks 
without sequelae. In the placebo group, one patient (0.5%) reported 
an SAE of a benign colon tumor. No patients in the Gelesis100 group 
reported an SAE. No deaths occurred during the study.
There were no significant differences in the serum levels of vitamins A, 
B1, B2, B6, B9, B12, and D between the two groups in the subcohort 
whose vitamin levels were measured.
In summary, other than an increase in overall gastrointestinal AEs, there 
was no difference in the incidence and severity of AEs between the 
Gelesis100 and placebo groups. In both treatment groups, most AEs 
were mild or moderate in intensity, occurred within the first 3 months, 
and resolved within 2 weeks (Table 4).
GLOW-EX results
GLOW-EX was offered to the last 52 completers of the GLOW study 
(Gelesis100 and placebo groups) who had lost ≥ 3% body weight from 
baseline. Of these eligible patients, 39 (21 from the Gelesis100 group 
and 18 from the placebo group) enrolled in GLOW-EX. Patients 
treated with Gelesis100 in GLOW achieved a mean of 7.1% (SD 2.8%) 
weight loss at the time of enrollment in GLOW-EX. Continuation of 
Figure 4 Percent change from baseline in glycemic control parameters (completers 
with baseline FPG ≥  90 mg/dL and not treated with antidiabetes medication). 
Baseline FPG was 100.9 mg/dL in the Gelesis100 group and 102.5 mg/dL in the 
placebo group. Mean percent change (95% CI) from baseline in FPG in Gelesis100 
(n = 121) and placebo (n = 111; P = 0.1872). Baseline fasting serum insulin was 11.5 
mU/L in the Gelesis100 group and 12.1 mU/L in the placebo group. Mean percent 
change (95% CI) from baseline in fasting serum insulin in Gelesis100 (n = 120) 
and placebo (n = 111; P = 0.0102). Baseline HOMA-IR was 2.9 in the Gelesis100 
group and 3.2 in the placebo group. Mean percent change (95% CI) from 
baseline in HOMA-IR in Gelesis100 (n = 120) and placebo (n = 111; P = 0.0080). 
*P < 0.05; **P < 0.01. FPG, fasting plasma glucose; HOMA-IR, homeostasis model 
assessment-insulin resistance.
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Gelesis100 resulted in a mean of 7.6% (SD 5.1%) weight loss at 48 
weeks (ITT population, P < 0.0001 from GLOW baseline), showing 
maintenance of weight loss at 48 weeks. Patients treated with pla-
cebo in GLOW achieved a mean of 7.1% (SD 4.1%) weight loss at the 
time of enrollment in GLOW-EX. Addition of Gelesis100 resulted 
in a mean of 9.4% (SD 6.4%) weight loss at 48 weeks (ITT popula-
tion, P < 0.0001 from GLOW baseline). GLOW-EX safety results 
were consistent with the GLOW safety data. During GLOW-EX, no 
SAEs were reported.
Discussion
Results from the GLOW study demonstrate that Gelesis100 is an 
 effective weight loss therapy that is safe and well tolerated. Repeated 
administration of Gelesis100 over 6 months resulted in significant 
weight loss over placebo (P = 0.0007). Although the placebo-adjusted 
weight loss was 2.1% and did not reach the 3% threshold, importantly, 
59% of patients treated with Gelesis100 lost ≥ 5% of their body weight 
(co-primary end point) and 27% lost ≥ 10%, versus 42% and 15% with 
placebo, respectively. The odds to achieve both thresholds were dou-
bled versus placebo (adjusted OR). Of note, Gelesis100 treatment had 
no increased safety risk, and only gastrointestinal AEs, when com-
bined, were reported at a higher (9%) incidence than with placebo. 
Notably, only five patients withdrew from the Gelesis100 group be-
cause of gastrointestinal-related AEs versus four from the placebo 
group.
New tools are needed to supplement lifestyle management for treatment 
of overweight and obesity. There is a particular need for treatments that 
produce significant weight loss without major AEs (11,14). The out-
standing safety profile of Gelesis100 combined with its demonstrated 
efficacy should make it an attractive option for obesity treatment.
There is wide interindividual variability in response to weight loss 
therapies, and it would be helpful to understand how to better match 
treatment to the patient (20). The availability of reliable weight loss 
predictors would increase the probability of patients achieving and 
maintaining weight loss and could improve cost-effectiveness (20). The 
GLOW study revealed the following two useful tools that could support 
a personalized approach utilizing Gelesis100 and guide clinicians in 
selecting patients who will benefit the most from treatment: FPG and 
weight loss achieved as early as 8 weeks of therapy.
In the FLOW pilot study, an unexpected association was observed 
between baseline FPG levels and the effectiveness of the treatment 
(18). The GLOW study replicated these findings. Despite the fact 
that in patients with prediabetes or drug-naive T2D the difference 
between the treatment groups for achieving ≥ 5% weight loss was 
not significant, as the thresholds for weight loss became higher and 
harder to achieve, the difference became substantial and signifi-
cant. Similarly, the increase in 5% responders over normoglycemic 
patients was the same in both treatment groups. However, a clear 
difference favoring Gelesis100 was observed in the 7.5% and 10% 
responder groups (Figure 3). When taking Gelesis100, the odds of 
achieving ≥ 10% weight loss were six times higher compared with 
placebo for patients with prediabetes or drug-naive T2D. This finding 
demonstrated a benefit for a higher-risk population otherwise known 
to be less responsive to therapy. Although this population was rela-
tively small (n = 68), these findings, in addition to the results of the 
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FLOW study, suggest that FPG could be a simple predictor that may 
be used as a tool for identifying patients who are both at higher clini-
cal risk and more likely to achieve greater levels of weight loss when 
treated with Gelesis100.
Early response to treatment is an additional tool to predict the effective-
ness of Gelesis100 treatment with a high level of precision. Results of 
AUC ROC analysis suggest that a weight loss of ≥ 3% after as few as 
8 weeks of treatment with Gelesis100 is predictive of a weight loss of 
≥ 5% after 6 months. Notably, early responders achieved a mean weight 
loss of 9.9% versus 2.1% in non-early responders at week 24. Although 
there are no overall increased safety risks with Gelesis100, predicting 
successful treatment early allows efficient use of resources and pro-
vides a key milestone to motivate patients with overweight or obesity.
Long-term weight loss maintenance is difficult to achieve solely with 
lifestyle modification interventions (21,22). Weight loss was main-
tained for an additional 24 weeks among the 21 participants who lost at 
least 3% with Gelesis100 after 6 months in the GLOW study and who 
were enrolled in the GLOW-EX study.
Considering the repeated intriguing findings in patients with elevated 
FPG and the observed reduction in insulin resistance in the Gelesis100 
group (Figure 4), future studies should confirm these findings and 
explore the underlying mechanisms of action.
Given the evident safety profile of Gelesis100, it is important to under-
take clinical studies in the pediatric population. Also, as the treatment 
of patients with overweight or obesity often involves multiple strate-
gies, future studies of Gelesis100 treatment in combination with other 
therapeutic approaches are warranted.
In conclusion, Gelesis100 is an effective and safe new nonsystemic 
therapy with a unique mechanism of action for overweight and obesity. 
Treatment doubles the odds of achieving clinically meaningful weight 
loss (≥ 5% and ≥ 10%). In addition, because of its highly desirable 
safety and tolerability profile, if approved, Gelesis100 could be con-
sidered a promising new therapy for the treatment of overweight and 
obesity.O
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